Peptide News Digest

Australia Clears Foundayo Pill, Wegovy in Children Aged 6 to 11, Ending Medicaid Coverage Cuts GLP-1 Use 84%

Australia clears the Foundayo pill, Wegovy cuts BMI 17.4% in young children, and ending Medicaid coverage cut GLP-1 prescriptions 84% in four states.

11 stories · Covering regulatory, clinical-trials, research, industry

Editor's Note

Australia cleared Lilly's Foundayo pill weeks after the Wegovy pill, and the EMA's drug committee told women on Mounjaro that their birth control pill may need backup. Approvals are not the same as access, though. A JAMA study found that when California, New Hampshire, Pennsylvania, and South Carolina stopped Medicaid coverage of weight-loss GLP-1s, prescriptions in those states fell about 84%. Federal employees face prior authorization, required behavioral therapy, and 50% cost sharing in most FEHB plans next year, and hundreds of Episcopalians are petitioning their church's pension group to keep coverage. On the science side, full STEP Young results show Wegovy lowered BMI by 17.4% in children aged 6 to 11, though no obesity drug is approved for that age group yet. Insulin and other peptides filled the rest of the day: the FDA cleared MiniMed's first tubeless pump, Utah asked diabetes patients to tell their stories for its insulin pricing lawsuit, and New Zealand's border seizures of suspected illegal peptides passed last year's total in six months.

7NEWS: Australia's TGA Clears Foundayo, the Second GLP-1 Weight-Loss Pill After the Wegovy Pill

Australia's Therapeutic Goods Administration has cleared Lilly's daily Foundayo pill for weight management and type 2 diabetes, 7NEWS reported on November 17 Australian time, weeks after the Wegovy pill was approved. It is available by private prescription but not yet listed on the Pharmaceutical Benefits Scheme, and Lilly Australia said trials enrolled more than 10,000 patients in 15 countries. Associate Professor Samantha Hocking said obesity and overweight now affect around 13 million Australian adults.

EMA Committee Backs Two Biosimilar Insulin Aspart Medicines and Warns Mounjaro May Make the Pill Less Reliable

At its November 9-12 meeting, the CHMP adopted positive opinions for Garzulys and Donrafylix, two biosimilar versions of the mealtime insulin aspart for adults and children aged 1 and older. The committee also adopted a letter to health professionals on Mounjaro (tirzepatide) and oral contraceptives: women using the pill are advised to add a barrier method for 4 weeks after starting Mounjaro and after each dose increase, or switch to a non-oral method.

CNBC: Full STEP Young Results Show Wegovy Lowered BMI 17.4% in Children Aged 6 to 11 Over 68 Weeks

In Novo Nordisk's trial of 167 children aged 6 to under 12 with obesity, all of whom also received diet and activity counseling, BMI fell 17.4% on Wegovy and rose 2.2% on placebo at 68 weeks for children who stayed on treatment, CNBC reported. Counting those who stopped, the gap was 16.2 percentage points. Novo said it saw no safety concerns for growth or puberty. No obesity drug is approved for children under 12, and Novo's Andrea Traina called long-term effects of earlier treatment "still an evidence gap."

Amylyx's Avexitide Cut Severe Low Blood Sugar Events 55% After Gastric Bypass in Phase 3 LUCIDITY Trial

In 78 adults with post-bariatric hypoglycemia after Roux-en-Y gastric bypass, daily 90 mg avexitide injections lowered the rate of level 2 and level 3 hypoglycemic events to 0.55 a week from 1.24 on placebo over 16 weeks, Amylyx reported at ObesityWeek. Avexitide is a peptide that blocks the GLP-1 receptor, the opposite of weight-loss GLP-1 drugs, to curb the insulin surges behind these crashes. Side effects were mainly stomach and injection-site reactions, with no treatment-related serious adverse events.

JAMA: Weight-Loss GLP-1 Prescriptions Fell 84% in Four States That Ended Medicaid Coverage on January 1

University of Pittsburgh researchers found that in California, New Hampshire, Pennsylvania, and South Carolina, Medicaid prescriptions for GLP-1s approved for weight loss fell from 2,914 to 421 per 100,000 beneficiaries between late 2025 and early 2026, versus 3,006 to 2,758 in 10 states that kept coverage. Pennsylvania's drop was 95.5%. The authors estimate 175,500 to 526,600 fewer beneficiaries may have filled prescriptions, and they saw no significant shift to diabetes-approved GLP-1s.

Federal News Network: FEHB Plans Will Require Behavioral Therapy and Prior Authorization for Weight-Loss GLP-1s in 2027

All Federal Employees Health Benefits and Postal Service plans will require documented participation in an intensive behavioral therapy program before and during treatment with obesity drugs in 2027, and most carriers are raising member cost sharing to 50%, Federal News Network reported. In SAMBA High, Wegovy will cost 500% more and Zepbound more than 400% more. An OPM inspector general report found GLP-1 spending at the two largest carriers rose from $392 million in 2019 to $2.6 billion in 2024.

Episcopal News Service: Hundreds Sign Letter Asking the Church Pension Group to Keep GLP-1 Coverage for Clergy in 2027

The "One Body" campaign wants the Church Pension Group to reconsider or phase in its decision to cover GLP-1 drugs only for type 2 diabetes in its Denominational Health Plan starting in 2027, Episcopal News Service reported. Organizer the Rev. Meghan Ryan, a Missouri priest, said she could face about $350 a month for Wegovy. The church's Medical Trust said plan changes cut its projected 2027 rate increase from 22.5% to 12.6%.

FDA Clears MiniMed Fit, MiniMed's First Tubeless Insulin Pump, With Up to Seven Days of Wear

MiniMed said the FDA cleared MiniMed Fit for people with type 1 or type 2 diabetes aged 7 and older. The waterproof pump holds 300 units of insulin, runs MiniMed's SmartGuard automated dosing, is controlled by a phone app, and will pair with Simplera Sync or Abbott's Instinct sensor. MiniMed expects a phased U.S. rollout in spring 2027, after an early customer phase.

Utah Asks Diabetes Patients to Share Insulin Costs for Its Lawsuit Against Insulin Makers and PBMs

Utah's Division of Consumer Protection is inviting current and past patients to describe buying and using diabetes medication over the past 10 years, to support the state's November 2023 lawsuit against insulin manufacturers, including Eli Lilly and Novo Nordisk, and pharmacy benefit managers, Utah News Dispatch reported via St. George News. The state says list prices of some insulins rose more than 1,000%. The companies deny the claims, and submissions may be subject to legal discovery.

RNZ: New Zealand Seized 398 Parcels of Suspected Illegal Peptides in Six Months, More Than in All of 2025

Ministry of Health figures show border officials intercepted 398 parcels containing peptides, suspected peptides, or SARMs in the six months to June, compared with 370 in all of 2025 and about 18 in 2023, RNZ reported. Medsafe has received seven adverse reaction reports possibly linked to peptides since a May safety alert, five involving products people believed contained retatrutide. Health NZ handed out 2,300 peptide injection kits through 190 pharmacies in the first six weeks of its needle exchange program.

Palatin Picks PL2001, a Long-Acting MC4R Peptide Built to Avoid Skin Darkening, for Rare Obesity Disorders

At ObesityWeek, Palatin Technologies presented animal and cell data on lipidated peptides that activate the MC4R appetite receptor while showing minimal to no activity at MC1R, the receptor behind the skin darkening seen with current MC4R drugs. The company said they reduced body weight and food intake in preclinical models. It has chosen PL2001 for development in hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, with first human studies targeted for the first half of 2027.